Literature DB >> 29224371

Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity.

Soo-Yeon Kim1, Whi-An Kwon2, Seung-Pil Shin1, Ho Kyung Seo3, Soo-Jeong Lim4, Yuh-Seog Jung1, Hyo-Kyung Han5, Kyung-Chae Jeong6, Sang-Jin Lee1.   

Abstract

In a previous report, 3-aminopropyl functionalized magnesium phyllosilicate (aminoclay) improved adenovirus transduction efficiency by shielding the negative surface charges of adenovirus particles. The present study analyzed the physicochemical characterization of the electrostatic complex of adenoviruses with aminoclay and explored whether it could be utilized for enhancing tumor suppressive activity in the bladder. As a result of aminoclay-adenovirus nanobiohybridization, its transduction was enhanced in a dose-dependent manner, increasing transgene expression in bladder cancer cells and in in vivo animal models. Physicochemical studies demonstrated that positively charged aminoclay led to the neutralization of negative surface charges of adenoviruses, protection of adenoviruses from neutralizing antibodies and lowered transepithelial electrical resistance (TEER). As expected from the physicochemical properties, the aminoclay enabled tumor-targeting adenoviruses to be more potent in killing bladder cancer cells and suppressing tumor growth in orthotopic bladder tumors, suggesting that aminoclay would be an efficient, versatile and biocompatible delivery carrier for intravesical instillation of adenoviruses.

Entities:  

Keywords:  Aminoclay; adenovirus; bladder cancer; gene therapy; transduction

Mesh:

Year:  2018        PMID: 29224371      PMCID: PMC6058485          DOI: 10.1080/10717544.2017.1413450

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  31 in total

1.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

2.  Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

Authors:  Jürgen Kuball; Shu Fen Wen; Joachim Leissner; Derek Atkins; Patricia Meinhardt; Erlinda Quijano; Heidrun Engler; Beth Hutchins; Daniel C Maneval; Michael J Grace; Mary Ann Fritz; Stefan Störkel; Joachim W Thüroff; Christoph Huber; Martin Schuler
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo.

Authors:  M A Croyle; X Cheng; A Sandhu; J M Wilson
Journal:  Mol Ther       Date:  2001-07       Impact factor: 11.454

4.  Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium.

Authors:  R J Connor; H Engler; T Machemer; J M Philopena; M T Horn; S Sutjipto; D C Maneval; S Youngster; T M Chan; J Bausch; J P McAuliffe; O Hindsgaul; T L Nagabhushan
Journal:  Gene Ther       Date:  2001-01       Impact factor: 5.250

5.  Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.

Authors:  J T Douglas; M Kim; L A Sumerel; D E Carey; D T Curiel
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

6.  Alteration of urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation, and changes in biliary excretion.

Authors:  F F Kadlubar; L E Unruh; T J Flammang; D Sparks; R K Mitchum; G J Mulder
Journal:  Chem Biol Interact       Date:  1981-01       Impact factor: 5.192

7.  Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.

Authors:  Motoyuki Yamashita; Charles J Rosser; Jain-Hua Zhou; Xin-Qiao Zhang; Robert J Connor; Heidrun Engler; Daniel C Maneval; Takashi Karashima; Bogdan A Czerniak; Colin P N Dinney; William F Benedict
Journal:  Cancer Gene Ther       Date:  2002-08       Impact factor: 5.987

8.  Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl.

Authors:  F F Kadlubar; K L Dooley; C H Teitel; D W Roberts; R W Benson; M A Butler; J R Bailey; J F Young; P W Skipper; S R Tannenbaum
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver.

Authors:  S R Babu; V M Lakshmi; G P Huang; T V Zenser; B B Davis
Journal:  Biochem Pharmacol       Date:  1996-06-28       Impact factor: 5.858

10.  Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.

Authors:  Hong-Jïan Zhu; Zhi-Qing Zhang; Xiang-Fu Zeng; Shou-Shun Wei; Zhi-Wen Zhang; Ying-Lu Guo
Journal:  Cancer Gene Ther       Date:  2004-04       Impact factor: 5.987

View more
  3 in total

1.  Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel.

Authors:  Ho Yub Yoon; In Ho Chang; Yoon Tae Goo; Chang Hyun Kim; Tae Hoon Kang; Soo-Yeon Kim; Sang Jin Lee; Seh Hyon Song; Young Mi Whang; Young Wook Choi
Journal:  Int J Nanomedicine       Date:  2019-08-05

Review 2.  Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism.

Authors:  Piotr Rzymski; Bartłomiej Perek; Robert Flisiak
Journal:  Vaccines (Basel)       Date:  2021-05-27

3.  Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.

Authors:  Jung Min Kim; Da Hye Kim; Hyo Jeong Park; Hyun Woo Ma; I Seul Park; Mijeong Son; So Youn Ro; Seokmann Hong; Hyo Kyung Han; Soo Jeong Lim; Seung Won Kim; Jae Hee Cheon
Journal:  J Nanobiotechnology       Date:  2020-09-15       Impact factor: 10.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.